Restor3d raises $23 million to expand bespoke additively manufactured musculoskeletal solutions
April 20, 2022
Restor3d, Durham, North Carolina, USA, has raised $23 million in an effort to expand the delivery of additively manufactured personalised surgical solutions across multiple musculoskeletal specialities, and to develop machine learning software to assist with patient-specific implant design.
Ken Gall PhD, co-founder of Restor3d and a Professor at Duke University, has stated that the company will be deploying the capital on the following:
- New product introductions and enhanced bespoke additively manufactured surgical solutions in upper/lower extremity, spine and trauma
- Ongoing development of machine learning enabled software for surgical planning and implant design
- Fundamental research, preclinical, and clinical studies
- Expansion of the commercial team to support market traction.
In early 2023, Restor3d intends to move into a new facility in Research Triangle Park that will expand capabilities for patient-specific digital design, in-house manufacturing of implants and instruments, as well as surgeon training and education labs.
Restor3d merged with Kinos Medical in 2021, a move which is said to have helped accelerate the company’s expansion into the high-growth extremity arthroplasty markets in the US. Restor3d has multiple FDA product clearances that span lower extremity, upper extremity, spine, and trauma and this new funding combined with the company’s additively manufactured implant & disposable instrument model are expected to enable simultaneous expansion across diverse markets.
